A Single-Arm, Open-label, Phase II Study Evaluating the Efficacy and Safety of Abemaciclib in Patients With Recurrent OligodendrogliomaUniversity of Pennsylvania
ClinicalTrials.gov Identifier: NCT03969706
Investigators at the University of Pennsylvania have started a Phase II, single-arm, open-label study looking how well abemaciclib (VerzenioTM, Lilly) works in patients with recurrent oligodendroglioma.
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to firstname.lastname@example.org for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.